Publicaciones científicas

TPS in prostate cancer

01-feb-1995 | Revista: Actas Urológicas Españolas

Rodríguez-Rubio FI, Monreal I, Robles JE, Martín-Marquina A, Abad JI, Rosell D, Berián JM.

Departamento de Urología, Facultad de Medicina, Universidad de Navarra, Pamplona.


A study of the tumour proliferation marker TPS in prostate cancer has been carried out.

The levels of this marker were determined in the following groups: controls (n = 51), prostate hyperplasia (n = 17), prostate cancer in clinical remission (n = 15), and progressive prostate cancer (n = 13). An upper normal limit of 129 U/l (percentile 95) was established.

When the progressive disease group was compared with the other groups, a significant difference (p < 0.001) was found. Sensitivity, specificity and positive predictive value obtained in order to dismiss progression were 71%, 94% and 62% respectively.

CITA DEL ARTÍCULO  Actas Urol Esp. 1995 Feb;19(2):131-3